Who Owns Dexilant?

• Parent Company:
• Ownership Type: Brand division
• Company Type: Privately Held

• Founded: 2009
• Founders: Takeda Pharmaceutical Company (internal development)

• Founded:
• Headquarters:
• Company Type: Privately Held

• Headquarters: Tokyo, Japan
• Manufacturing / Operations: Japan, United States, Belgium, Germany

Dexilant operates under Takeda Pharmaceutical Company's comprehensive sustainability framework, which encompasses environmental stewardship, ethical business practices, and corporate responsibility initiatives across global operations. As part of Takeda's gastroenterology portfolio, Dexilant benefits from the company's ambitious environmental targets and ethical manufacturing standards.

Takeda has established science-based targets for greenhouse gas emissions reduction that are consistent with limiting global temperature rise to 1.5°C above pre-industrial levels, as recognized by the Science Based Targets initiative in 2020. The company has been included in the Dow Jones Sustainability Asia Pacific Index for 13 consecutive years through 2022, demonstrating sustained commitment to environmental performance.

Environmental Manufacturing Practices: Dexilant production facilities participate in Takeda's global environmental initiatives, including carbon reduction programs, water conservation efforts, and waste management systems. The company has achieved recognition for its sustainable packaging innovations, receiving WorldStar Global Packaging Awards for pioneering use of bio-polyethylene in pharmaceutical packaging materials.

Supply Chain Ethics: Takeda maintains strict ethical sourcing standards for Dexilant raw materials and manufacturing components. The company implements comprehensive supplier responsibility programs that ensure fair labor practices, environmental compliance, and quality standards across all production facilities involved in Dexilant manufacturing.

Climate Leadership: Takeda's inclusion on CDP's 2022 A list for climate change leadership and transparency reflects the company's commitment to environmental disclosure and climate action. Dexilant manufacturing sites contribute to these efforts through energy efficiency improvements and renewable energy adoption.

Green Laboratory Certification: Takeda's quality laboratory in Singapore, which supports testing and quality assurance for products including Dexilant, has achieved the highest level of green lab certification from My Green Lab, demonstrating leadership in sustainable laboratory practices.

Ethical Marketing and Sales: Takeda maintains strict compliance programs governing the promotion and distribution of Dexilant, ensuring all marketing activities adhere to regulatory requirements and ethical standards in healthcare pharmaceutical marketing.

Dexilant has received recognition primarily as part of Takeda Pharmaceutical Company's broader pharmaceutical achievements and innovation in gastroenterology treatments, rather than as an independent brand with separate accolades.

Parent Company Recognition: Takeda Pharmaceutical Company has received numerous awards and recognitions that encompass the Dexilant brand as part of Takeda's gastroenterology portfolio. These include consistent inclusion in the Dow Jones Sustainability Asia Pacific Index for 13 consecutive years through 2022, demonstrating corporate leadership in pharmaceutical sustainability and responsibility.

Environmental Innovation Awards: As part of Takeda's pharmaceutical operations, Dexilant benefits from the company's recognition for sustainable packaging innovations. Takeda received two WorldStar Global Packaging Awards from the World Packaging Organization for pioneering use of bio-polyethylene in pharmaceutical primary packaging and secondary packaging, innovations that apply across Takeda's product portfolio including gastroenterology medications.

Climate Leadership Recognition: Takeda's inclusion on CDP's 2022 A list for climate change leadership and transparency reflects environmental achievements that benefit all Takeda products, including Dexilant. This recognition demonstrates the company's commitment to environmental disclosure and climate action in pharmaceutical manufacturing.

Green Laboratory Certification: Takeda's quality laboratory in Singapore, which supports testing and quality assurance for products including Dexilant, achieved the highest level of green lab certification from My Green Lab. This recognition represents leadership in sustainable laboratory practices that support pharmaceutical quality assurance across Takeda's product lines.

Science-Based Targets Recognition: Takeda's greenhouse gas emissions reduction targets, which were recognized by the Science Based Targets initiative in 2020 as being consistent with limiting global temperature rise to 1.5°C, encompass environmental achievements that benefit Dexilant manufacturing and distribution operations.

Pharmaceutical Innovation: While Dexilant itself has not received independent awards, its development as an innovative proton pump inhibitor represents Takeda's commitment to advancing gastroenterology treatments. The drug's approval in 2009 and subsequent expansion to adolescent patients in 2016 demonstrate Takeda's success in bringing innovative pharmaceutical solutions to market.

Dexilant has faced significant legal challenges related to antitrust allegations and market competition practices, though the medication itself has not been subject to major product safety recalls.

Pay-for-Delay Antitrust Lawsuits: Dexilant has been at the center of multiple antitrust lawsuits alleging that Takeda engaged in "pay-for-delay" agreements to keep generic versions of the medication off the market. In March 2025, major retailers including Walgreens, Kroger, Albertsons, and H-E-B filed a federal antitrust lawsuit in California accusing Takeda and TWi Pharmaceuticals of conspiring to delay the release of a generic version of Dexilant. The retailers alleged that Takeda paid TWi to delay generic market entry until January 2022, despite applicable patent expirations that would have allowed generic entry as early as June 2020.

CVS Antitrust Lawsuit: Six months after the initial retailer lawsuit, CVS filed a similar antitrust complaint in September 2025 against Takeda and TWi Pharmaceuticals. CVS alleged that the "reverse payment" arrangement increased its expenses in purchasing Dexilant for customers and prevented competition from other generic drug manufacturers even after Takeda's patent protection had expired.

Court Proceedings: In February 2026, a federal court ruled that Takeda and TWi Pharmaceuticals must face most of the proposed antitrust class action, allowing the lawsuit to proceed. The case represents one of the significant pharmaceutical antitrust challenges involving alleged pay-for-delay schemes that prevent timely generic competition and maintain higher drug prices for consumers.

Market Impact: The alleged delayed generic entry affected retailers and consumers who continued to pay higher prices for brand-name Dexilant due to lack of generic competition. The lawsuits highlight ongoing concerns about pharmaceutical pricing practices and the use of patent settlements to extend market exclusivity beyond standard patent protection periods.

Parent Company Controversies: While Dexilant itself has not faced product safety recalls, Takeda Pharmaceutical Company has faced other pharmaceutical controversies, including a $2.4 billion settlement in 2014 over thousands of lawsuits related to its diabetes drug Actos, which was associated with increased bladder cancer risk. Takeda has also faced regulatory scrutiny over its marketing practices for proton pump inhibitors as a class.

Regulatory Scrutiny of PPIs: The proton pump inhibitor drug class, which includes Dexilant, has faced increased regulatory and medical scrutiny regarding long-term use risks. Studies have associated PPIs with potential kidney-related conditions, stroke risks, bone fractures, and serious infections, leading to questions about over-prescription practices across the entire drug category.